Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach

• Published in: BMC cancer Vol. 24; no. 1; pp. 1328 - 5
• Main Authors: Neviere, Zoé, Blanc-Fournier, Cécile, Guizard, Anne-Valérie, Elie, Nicolas, Giffard, Florence, Lequesne, Justine, Emile, George, Poulain, Laurent, Lasnon, Charline
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.10.2024; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Analysis; Antibodies; Antigens, Surface - metabolism; Biological markers; Biomarkers; Biomarkers, Tumor - metabolism; BRCA1 protein; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cancer therapies; Care and treatment; Clinical trials; Diagnosis; Digitization; Female; Glutamate Carboxypeptidase II - metabolism; Human FOLH1 protein; Humans; Immune system; Immunohistochemistry; Male; Middle Aged; Mutation; Nuclear medicine; Nuclear Medicine - methods; Patients; Precision Medicine - methods; Prostate cancer; PSMA; Radiation therapy; Retrospective Studies; Risk factors; Testing; Theranostic Nanomedicine - methods; Tumors; France; Nuclear medicine; PSMA; Breast cancer; Human FOLH1 protein
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-024-13065-0

Further research is still needed to fully understand the potential of prostate-specific membrane antigen (PSMA) in breast cancer (BC) and to develop and optimize targeted therapies and imaging modalities. The objective of this study was to present a comprehensive analysis of immunohistochemistry data on PSMA staining in BC and to discuss its potential value in a theranostic approach. Fifty-eight male and female patients were randomly selected from a retrospective database of patients who underwent surgery for breast cancer between January 2012 and December 2017 and for whom a specimen is available in our tumour library. Immunodetection of PSMA and CD31 was performed on serial slides. The digitized slides were reviewed and analysed by an experienced pathologist. Additionally, the corresponding TIFF images were processed to calculate the percentage of positive neovessels. Eighteen patients (31.6%) had no expression, 29 (50.9%) had PSMA neovascular expression scored as "1", and 10 (17.5%) had neovascular expression scored as "2". Digital immunohistochemistry analysis for this last specific group of patients showed a median proportion of positive neovessels equal to 5% (range: 3-19). A multivariable logistic regression demonstrated that the odds of PSMA positivity were 4.55 times higher in non-luminal tumours and decreased by a factor of 0.12 in lobular subtypes. There was no association between sex or the presence of a germline BRCA1/2 mutation and PSMA expression in tumours. Our study highlights generally low neovascular expression of PSMA in specific histopathological subtypes of breast cancer, which will likely hamper the development of an adequate theranostic strategy. The procedure has been retrospectively registered to the French National Institute for Health Data (N° F20220615153900).